INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO

Core Viewpoint - Novo Nordisk has significantly lowered its sales outlook for 2025 due to increased competition for its drugs Ozempic and Wegovy, leading to a substantial drop in its stock price [3]. Group 1: Company Performance - On July 29, 2025, Novo Nordisk reduced its sales forecast for 2025, attributing the change to heightened competition in the market for its key products [3]. - Following the announcement, Novo Nordisk's American Depositary Receipt (ADR) price decreased by $15.06, or 21.83%, closing at $53.94 per ADR on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or unlawful business practices by Novo Nordisk and its officers or directors [1].